Literature DB >> 20549588

[Quality rating of follow-up examinations conducted on breast cancer patients].

K-J Winzer1, J Bellach.   

Abstract

For breast centre certification, follow-up care data have to be presented, although the further treatment is carried out outside of the hospital. An analysis of 2062 patients with their first operation (breast cancer and carcinoma in situ) occurring between 1.1.1984 and 31.12.1998 has been conducted. The tracking of follow-up results ended on 1.7.2007. The survival of breast cancer patients appears to be superior in the pure clinical register than with cross-linking with additional registers (Epidemiological Cancer Register and registration of address office). The outcome of this is that the completed feedback of the cases of death (Cancer Register) and of living patients (registration of address office) increases the qualitative statement. The compliance with the data security laws may be ensured by pseudo-anonymisation. Georg Thieme Verlag Stuttgart, New York.

Entities:  

Mesh:

Year:  2010        PMID: 20549588     DOI: 10.1055/s-0030-1247381

Source DB:  PubMed          Journal:  Zentralbl Chir        ISSN: 0044-409X            Impact factor:   0.942


  3 in total

1.  [Compliance of patients concerning recommended radiotherapy in breast cancer : Association with recurrence, age, and hormonal therapy].

Authors:  K-J Winzer; C Gruber; H Badakhshi; M Hinkelbein; C Denkert
Journal:  Strahlenther Onkol       Date:  2012-08-05       Impact factor: 3.621

2.  Long-Term Analysis of Ab-2 (Clone SN3b) Immunoreactivity as a Prognostic Factor in Breast Carcinoma.

Authors:  Klaus-Jürgen Winzer; Joachim Bellach; Glen Kristiansen
Journal:  Breast Care (Basel)       Date:  2015-03-26       Impact factor: 2.860

3.  Long-term analysis to objectify the tumour grading by means of automated microscopic image analysis of the nucleolar organizer regions (AgNORs) in the case of breast carcinoma.

Authors:  Klaus-Jürgen Winzer; Joachim Bellach; Peter Hufnagl
Journal:  Diagn Pathol       Date:  2013-04-08       Impact factor: 2.644

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.